Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 08 Aug 2022
SMC - August 2022 decisions
8 August 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 08 Aug 2022
Lilly's Taltz (ixekizumab) now available in new, citrate free formulation to reduce injection site pain for improved patient experience
8 August 2022 - Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated ...
Posted by Michael Wonder on 08 Aug 2022
Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring
8 August 2022 - Mayne Pharma and Mithra Pharmaceuticals are pleased to announce that the U.S. FDA has granted approval ...
Posted by Michael Wonder on 08 Aug 2022
Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...
Posted by Michael Wonder on 07 Aug 2022
Democrats will have to limit their drug pricing reforms to Medicare to comply with Senate rules
6 August 2022 - Democrats will likely have to axe two provisions from their drug pricing plan to fit in ...
Posted by Michael Wonder on 07 Aug 2022
Drug price bill pruned in Senate in partial industry win
6 August 2022 - Medicare to be allowed to negotiate drug prices for first time. ...
Posted by Michael Wonder on 07 Aug 2022
Myovant Sciences and Pfizer receive U.S. FDA approval of Myfembree, a once daily treatment for the management of moderate to severe pain associated with endometriosis
5 August 2022 - Data from the Phase 3 SPIRIT program showed Myfembree reduced menstrual pain and non-menstrual pelvic pain in ...
Posted by Michael Wonder on 07 Aug 2022
Australians forced to pay for methadone and other drugs to get off addictive PBS medication
7 August 2022 - Aussie taxpayers are subsidising addictive pain medication but not the treatments that help get patients off the ...
Posted by Michael Wonder on 07 Aug 2022
Health insurance premiums are heading higher but by how much?
6 August 2022 - Australians are expected to pay significantly more for health insurance but talk of a double digit premium ...
Posted by Michael Wonder on 06 Aug 2022
New Zealand allowed pharmacists to dispense COVID-19 antivirals and 'everyone realised it was a win'
6 August 2022 - With Australians dying from COVID-19 every day and nearly 5,000 people in hospital with the disease, experts ...
Posted by Michael Wonder on 06 Aug 2022
US Government about to get long awaited powers on drug pricing
6 August 2022 - Pharma rarely loses in Washington. For years, the industry has successfully defeated US Government efforts to rein ...
Posted by Michael Wonder on 06 Aug 2022
Obesity drug supply delay not unusual says Novo Nordisk CEO
4 August 2022 - Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy (semagutide) on Thursday, ...
Posted by Michael Wonder on 06 Aug 2022
Patients seeking novel weight loss drugs find a ‘wild west’ of online prescribers
4 August 2022 - Briana Lawson was ready to knock her diabetes into remission. For years, the 47 year old ...
Posted by Michael Wonder on 05 Aug 2022
Health Minister Mark Butler ‘terrified’ of low GP numbers as bulk billing declines
6 August 2022 - Federal Health Minister Mark Butler has acknowledged there will be “terrible consequences” if general practice continues ...
Posted by Michael Wonder on 05 Aug 2022
FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer
5 August 2022 - On 5 August 2022, the FDA approved darolutamide (Nubeqa, Bayer) tablets in combination with docetaxel for ...